Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Change in disability score · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 61 participantsModerate
Findings
What do systematic reviews say?
3,092 questions · 3,199 findings · 339 reviews · Headline outcomes only
No studies found 714 · 22.3%GRADE not reported 181 · 5.7%Very low 695 · 21.7%Low 908 · 28.4%Moderate 568 · 17.8%High 133 · 4.2%
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Muscle strength · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 16 participantsLow
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Acquiring the ability to stand or walk · non‐ambulatory children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Change in quality of life · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 54 participantsVery low
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Change in pulmonary function · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 24 participantsLow
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 61 participantsModerate
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Adverse events related to treatment · non‐ambulatory children with SMA types II and III
Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.32 [0.92, 1.89]1 study · 61 participantsModerate
Osmotic‐release oral system methylphenidate vs placebo
Seizure frequency · people with ADHD and epilepsy
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 33 participantsLow
Osmotic‐release oral system methylphenidate vs placebo
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyRR 2.8 [1.14, 6.89]1 study · 33 participantsModerate
Osmotic‐release oral system methylphenidate vs placebo
Seizure severity · people with ADHD and epilepsy
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 33 participantsLow
Osmotic‐release oral system methylphenidate vs placebo
50% or greater reduction in seizure frequency · people with ADHD and epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Osmotic‐release oral system methylphenidate vs placebo
ADHD symptoms · people with ADHD and epilepsy
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 33 participantsLow
Osmotic‐release oral system methylphenidate vs placebo
Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 33 participantsModerate
Oral omega‐3 PUFAs plus conventional therapy vs conventional therapy
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral omega‐3 PUFAs plus conventional therapy showed no clear difference in dry eye symptoms, measured using the OSDI score (ranging from 0 to… compared with conventional therapy alone (low certainty).
1 finding from 1 review
- Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 70 participantsLow
Oral omega‐3 PUFAs plus conventional therapy vs conventional therapy
Ocular surface staining · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
- Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral omega‐3 PUFAs plus conventional therapy vs conventional therapy
Aqueous tear production · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
- Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral omega‐3 PUFAs plus conventional therapy vs conventional therapy
Tear film stability · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
- Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral omega‐3 PUFAs plus conventional therapy vs conventional therapy
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
- Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral omega‐3 PUFAs plus conventional therapy vs conventional therapy
Adverse events at 1‐month · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
- Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg/kg 20 days) (low certainty).
1 finding from 1 review
- Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes onlyRR 1.05 [0.9, 1.23]7 studies · 676 participantsLow